CAPN3基因3′UTR复发变异凸显非编码变异在肢带型肌营养不良中的诊断价值
研究纳入13例来自11个无亲缘关系的家庭、携带CAPN3 c.*534T>C变异且表现为持续性高肌酸激酶血症(多伴近端肌无力和肌痛)的患者,通过临床评估、肌肉活检、肌肉MRI、计算机分析及荧光素酶报告基因实验,发现该非编码变异通过创建RBFOX1结合位点破坏转录后调控,导致calpain-3表达缺失或显著降低,提示3′UTR变异在孟德尔遗传病中的诊断价值。
要点
- CAPN3 c.*534T>C非编码变异与持续性高肌酸激酶血症及近端肌无力相关。
- 该变异在计算机分析中创建RBFOX1新结合位点,荧光素酶实验支持其调控calpain-3表达。
- 3′UTR变异可影响mRNA稳定性与蛋白表达,在未解决遗传病例中应系统探查非编码区。
核心结论
- 复发性非编码CAPN3变异通过破坏转录后调控导致疾病,3′UTR变异可影响mRNA稳定性和蛋白表达,这一原则适用于神经肌肉及其他孟德尔遗传病。
研究设计与样本
- 对携带CAPN3 c.*534T>C变异的个体进行临床评估(含肌肉活检和肌肉MRI)、计算机分析(miRNA结合、mRNA二级结构、poly-A尾创建或破坏、RNA结合蛋白基序)及荧光素酶报告基因实验(含或不含RBFOX1共表达)。
主要发现
- 共识别13例来自11个无亲缘关系的家庭、表现为持续性高肌酸激酶血症(常伴近端肌无力和肌痛)的个体,均携带c.*534T>C变异合并一个既往发现的杂合CAPN3变异。
- Western blot分析一致显示calpain-3表达缺失或显著降低,肌肉RNA测序显示CAPN3水平降低。
- 计算机分析提示c.*534T>C变异创建了RNA结合蛋白RBFOX1的新结合位点,荧光素酶报告基因实验支持该变异对calpain-3表达的调控效应。
临床怎么用
- 作者认为,3′UTR变异虽常难以解读为致病性,但可能具有治疗可操作性,凸显在未解决遗传病例中系统研究非编码区的重要性。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Objective A substantial proportion of individuals with suspected genetic conditions, including neuromuscular disorders, lack a definitive molecular diagnosis. Non-coding variants, particularly those in the 3′ untranslated region (3´UTR), which regulate mRNA stability, translation, and localization, may underlie part of this gap. We investigated the clinical, genetic, and functional relevance of a novel 3′UTR variant in CAPN3 in individuals with persistent hyperCKemia, most of whom also presented with proximal muscle weakness. Methods Clinical assessment, including muscle biopsy and muscle magnetic resonance imaging (MRI), was performed in individuals harboring the CAPN3 c.*534T>C variant. In silico analyses included the assessment of miRNA binding, mRNA secondary structure, creation or disruption of a poly-A tail, and RNA-binding protein (RBP) motifs. A luciferase reporter assay with the c.*534T>C and reference sequence, in the presence or absence of RBFOX1 co-expression, was performed. Results We identified 13 individuals from 11 unrelated families presenting with persistent hyperCKemia, commonly accompanied by proximal muscle weakness and myalgia, all harboring the c.*534T>C variant in combination with a previously identified heterozygous CAPN3 variant. Western blot analyses consistently demonstrated absent or markedly reduced calpain-3 expression, and muscle RNA sequencing (RNAseq) showed reduced CAPN3 levels. In silico analyses indicated that the c.*534T>C variant creates a novel binding site for the RNA-binding protein RBFOX1. Luciferase reporter assays supported a regulatory effect of the identified variant on calpain-3 expression. Interpretation Our results show that a recurrent non-coding CAPN3 variant causes disease by disrupting post-transcriptional regulation and demonstrate a generalizable principle, as 3′UTR variants can affect mRNA stability and protein expression across neuromuscular and other Mendelian diseases. Although often difficult to interpret as pathogenic, these variants can be therapeutically actionable, highlighting the importance of systematically investigating non-coding regions in unsolved genetic cases. ANN NEUROL 2026
引用
- Annals of Neurology:A Recurrent 3′UTR Variant in CAPN3 Highlights the Diagnostic Impact of Non‐Coding Variants in Limb‐Girdle Muscular Dystrophies
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。